HSPA5 and central nervous system cancer: Other preclinical studies have investigated the ability of HSPA5 inhibitors, antibodies, and other agents that bind to and inhibit HSPA5 to reduce glioma cells’ viability and enhance the sensitivity to chemo-radiotherapy.